FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen paying Arrowhead for traits to develop cardiovascular drugs
Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
Amgen announces positive results for migraine drug
Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →
Largest industrial building in Thousand Oaks sells for $37 million
The largest industrial building in Thousand Oaks was sold for $37 million, according to CBRE. Van Nuys-based real estate company Majestic Asset Management purchased the fully leased property at 1461-1475 Lawrence Drive from Austin, Texas-based Western National Life Insurance Co., a subsidiary of AIG. Majestic secured a $26.6 million balance sheet loan for the deal, Read More →
FDA approves Amgen biosimilar of AbbVie’s Humira
The Food and Drug Administration approved Amgen’s Humira biosimilar Sept. 23. Amjevita, formerly known as ABP 501 and made by Thousand Oaks-biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based competitor AbbVie, typically costs $20,000 per year Read More →
Make sure you know how the deed to your marital home lists the title
By Lisa Spiwak When a married couple goes to the escrow office to sign the documents to their new home, they are thinking about many things. Their minds are swirling with thoughts of the mortgage payment, furniture placement, the moving company, landscaping, area schools, etc. The last thing they are thinking about is how the Read More →
SOAR creates disparity in land values
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
